Wake Forest University has established a clinical consortium to provide six times per week nocturnal home hemodialysis for the NIH RFA for Frequent Hemodialysis Clinical Trials. This consortium consists of ten clinical sites located in the eastern United States, eastern Canada and the Midwestern United States. The consortium includes four of the largest nocturnal home hemodialysis programs in the United States, located in Lynchburg, VA, Saratoga Springs, NY, New York City, NY and Kansas City, MO and one of the largest nocturnal home hemodialysis programs in Canada at London, Ontario. Our clinical centers have more than 190 patient-years of experience with nocturnal home hemodialysis and have provided more than 60,000 home nocturnal hemodialysis treatments. The one year mortality rate for patients receiving nocturnal home hemodialysis at these centers is 4.7% (based on 84.9 patient-years of follow-up), significantly less than the 16.6% mortality rate observed in the NIH sponsored HEMO Study. The observed one year mortality rate for this cohort was 4, compared to an expected mortality rate of 15.8 (chi-square = 8.8, p < 0.005). This consortium proposes to randomize chronic end stage renal disease patients to either six times per week nocturnal home hemodialysis or standard three times per week hemodialysis. Patients will be assessed for the suitability of nocturnal home hemodialysis via a standardized protocol during the baseline period. Those patients that are found to be suitable will then be randomized. Patients will be followed for 12 to 18 months. The primary goals of this study will be to determine the feasibility of randomizing patients into this trial. The primary outcome for the study will be all-cause hospitalizations. Secondary outcomes will include mortality, protein and energy intake, anthropometrics, quality of life, functional status and physical activity. Laboratory data, dialysis parameters and patient medications will also be collected to assess the impact of the interventions on hypertension, anemia, and secondary hyperparathyroidism and electrolyte abnormalities. All hospitalizations, including inpatient and outpatient access interventions, will also be tracked. Direct cost estimates of the two different hemodialysis treatments from a limited societal perspective will also be obtained. Patient safety will be monitored by an external Data Safety and Monitoring Board.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK066480-02
Application #
6803608
Study Section
Special Emphasis Panel (ZDK1-GRB-2 (O1))
Program Officer
Eggers, Paul Wayne
Project Start
2003-09-30
Project End
2007-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
2
Fiscal Year
2004
Total Cost
$800,000
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Chan, Christopher T; Kaysen, George A; Beck, Gerald J et al. (2018) Changes in Biomarker Profile and Left Ventricular Hypertrophy Regression: Results from the Frequent Hemodialysis Network Trials. Am J Nephrol 47:208-217
Lo, Joan C; Beck, Gerald J; Kaysen, George A et al. (2017) Thyroid function in end stage renal disease and effects of frequent hemodialysis. Hemodial Int 21:534-541
Rocco, Michael V; Daugirdas, John T; Greene, Tom et al. (2015) Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal Trial. Am J Kidney Dis 66:459-68
Rocco, Michael V; Lockridge Jr, Robert S; Beck, Gerald J et al. (2011) The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int 80:1080-91
Rocco, Michael V (2011) Nocturnal home hemodialysis: which of your patients should choose this modality? Contrib Nephrol 171:17-24
Rocco, Michael V; Larive, Brett; Eggers, Paul W et al. (2011) Baseline characteristics of participants in the Frequent Hemodialysis Network (FHN) daily and nocturnal trials. Am J Kidney Dis 57:90-100
Daugirdas, John T; Depner, Thomas A; Greene, Tom et al. (2010) Effects of reduced intradialytic urea generation rate and residual renal clearance on modeled urea distribution volume and Kt/V in conventional, daily, and nocturnal dialysis. Semin Dial 23:19-24
Pipkin, Mary; Eggers, Paul W; Larive, Brett et al. (2010) Recruitment and training for home hemodialysis: experience and lessons from the Nocturnal Dialysis Trial. Clin J Am Soc Nephrol 5:1614-20
Rocco, Micheal V (2009) Short daily and nocturnal hemodialysis: new therapies for a new century? Saudi J Kidney Dis Transpl 20:1-11
Rocco, Michael V (2007) More frequent hemodialysis: back to the future? Adv Chronic Kidney Dis 14:e1-9